Clinical Trial Detail

NCT ID NCT02115048
Title Clinical Study for the Treatment of Breast Cancer the Patient Will Receive Afatinib Plus Letrozole or Letrozole Alone
Recruitment Completed
Gender female
Phase Phase II
Variant Requirements yes
Sponsors Translational Research in Oncology
Indications

Her2-receptor negative breast cancer

Therapies

Afatinib

Letrozole

Age Groups: adult

Additional content available in CKB BOOST